Britain and America have forged a major trade agreement that will ensure no duties on UK drug shipments going into the US market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to increase expenditure on drugs through the National Health Service (NHS). This pledge ensures that duties on these crucial goods will be held at nothing for a timeframe of 36 months.
This development is in response to earlier statements to dramatically increase tariffs on patented drug imports, with potential rates discussed reaching double the cost.
"This deal between the United Kingdom bolsters the international landscape for innovative medicines and brings long-overdue equity to U.S.–U.K. drug exports," an announcement noted.
Trade Significance
Medicines are one of the UK's most significant export categories to the America, which is clearly the primary destination for major UK drugmakers.
Statistics show that in the one-year period to the end of the third quarter, the UK sold pharmaceutical products worth over eleven billion pounds to the US. This value made up nearly one-fifth of British export trade in that timeframe.
"This agreement safeguards employment, boosts investment and sets the stage for the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary commented.
Detailed UK Commitments
The deal involves several notable commitments from the United Kingdom:
- Revised Affordability Limit: The UK will lift the affordability limit at which it deems new medicines to be prohibitively costly by 25%.
- Higher Drug Budget: There is a target to increase overall health service expenditure on medicines from 0.3 percent of the national economy to 0.6% over the next decade.
- Refund Ceiling: The sum drug companies must pay back to the NHS to stay within budget will be capped at fifteen percent. In the past, refunds were more than twenty percent.
Recent Tensions
The pact comes amid a long-running dispute between the sector and the ministers over spending levels and regulatory access.
This friction were exacerbated by arguments that US patients were paying significantly more for the same drugs than people in the UK and Europe.
In recent months, several significant drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar investments have been announced toward American operations.
The Science Minister stated that the NHS had to spend more on treatments, noting that its budget allocation on drugs had decreased as a proportion of its overall budget over the past decade.
